Medivir strengthens its R&D organization

  Medivir strengthens its R&D organization

Business Wire

HUDDINGE, Sweden -- March 21, 2013

Regulatory News:

Medivir AB (OMX: MVIR) today announced that the company will divide its
current R&D organization into two parts, Discovery Research and Development,
and strengthen the R&D leadership to prepare for future strategic and
operational opportunities.

Recruitment of an international research head

The research organization will be led by Richard Bethell, who will assume the
position as Executive Vice President Discovery Research on April 22. Richard,
who originally is from the UK, has a broad background within drug discovery
and development, with nearly 25 years’ experience from the pharmaceutical
industry in companies like Glaxo Wellcome, Pfizer and Shire. He joins Medivir
from Boehringer Ingelheim in Canada, where he was employed as Vice President,
Biological Sciences. His proven leadership has previously contributed to the
timely delivery of high quality candidate drugs for clinical development.
Richard Bethell has a D. Phil. in Chemistry from the University of Oxford, UK.

“We are very pleased that Richard has chosen to join Medivir. His solid
expertise and experience, especially within virology, will make the company
even stronger. That, together with an efficient development organization, is
important for our ambition to become a profitable and rapidly growing
pharmaceutical company”, says Maris Hartmanis, Medivir’s CEO.

Charlotte Edenius, who currently has the role of Executive Vice President R&D
at Medivir, will become responsible for the development organization. In her
new role as Executive Vice President Development, she will drive Medivir’s
non-clinical and clinical development following the selection of candidate

Medivir’s Executive Vice President Commercial, Henric Juserius, has decided to
leave the company. His departure will not affect the direction of the
commercial operations.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor in late phase III clinical development
for hepatitis C that is being developed in collaboration with Janssen R&D

Medivir has also a broad product portfolio with prescription pharmaceuticals
in the Nordics.

For more information about Medivir AB, please visit the Company’s website:

Medivir is a collaborative and agile pharmaceutical company with an R&D focus
on infectious diseases and a leading position in hepatitis C. We are
passionate and uncompromising in our mission to develop and commercialize
innovative pharmaceuticals that improve people’s lives.

This information was brought to you by Cision


Medivir AB
Maris Hartmanis, CEO
phone +46 (0)8 407 64 30
Press spacebar to pause and continue. Press esc to stop.